Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Camp4 Therapeutics (CAMP) Change in Cash (2023 - 2026)

Camp4 Therapeutics' Change in Cash history spans 3 years, with the latest figure at $34.9 million for Q4 2025.

  • On a quarterly basis, Change in Cash fell 43.3% to $34.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $46.1 million, a 79.64% increase, with the full-year FY2025 number at $46.1 million, up 79.64% from a year prior.
  • Change in Cash hit $34.9 million in Q4 2025 for Camp4 Therapeutics, down from $36.2 million in the prior quarter.
  • Over the last five years, Change in Cash for CAMP hit a ceiling of $61.5 million in Q4 2024 and a floor of -$14.7 million in Q1 2025.
  • Historically, Change in Cash has averaged $6.6 million across 3 years, with a median of -$10.3 million in 2025.
  • Biggest five-year swings in Change in Cash: soared 608.82% in 2024 and later plummeted 43.3% in 2025.
  • Tracing CAMP's Change in Cash over 3 years: stood at -$12.1 million in 2023, then soared by 608.82% to $61.5 million in 2024, then plummeted by 43.3% to $34.9 million in 2025.
  • Business Quant data shows Change in Cash for CAMP at $34.9 million in Q4 2025, $36.2 million in Q3 2025, and -$10.3 million in Q2 2025.